V Profile press fitting ,V Profile stainless steel plumbing fitting , DVGW PRESS FITTING Wenzhou Gaoya Light Industry Machinery Co.,ltd. , https://www.hongyafitting.com
Medical Network November 15th, on November 13, Hengrui Medicine issued an announcement saying that it has recently received the "Clinical Trial Notice" issued by the State Food and Drug Administration, and will carry out the injection of meloxicam in the near future. Phase I clinical trial. It is reported that meloxicam suspension injection is a non-steroidal anti-inflammatory drug for intravenous injection, which is intended for the treatment of moderate to severe pain after surgery. At present, there is no such product approved for listing at home and abroad.
　　 Table 1: Basic situation of drugs
(Source: Announcement of listed company)
According to reports, Hengrui Medicine submitted a clinical trial application for the injection of meloxicam suspension to the State Food and Drug Administration on June 4, 2018. The product is a non-steroidal anti-inflammatory drug for intravenous injection. It is intended to be used for the treatment of moderate to severe pain after surgery.
Figure 1: Sales of non-steroidal anti-inflammatory and anti-rheumatic drugs in Chinese public medical institutions in 2013-2017 (Unit: 10,000 yuan)
(Source: Minernet China's public medical institutions terminal competition pattern)
According to the data from the intranet, the market size of non-steroidal anti-inflammatory and anti-rheumatic drugs in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) has risen to 132 in 2017. 100 million yuan, the growth rate is 15.55%.
According to the announcement, at present, RecroPharma Company of the United States has submitted a new drug listing application for this product to the FDA. There is no such product in the clinical trial stage in China, and there is no such product approved for listing at home and abroad. Up to now, Hengrui Medical has invested about 2.96 million yuan in research and development.
　　 Source: Listed company announcement, Minenet database